Cargando…
Systems analysis of intracellular pH vulnerabilities for cancer therapy
A reverse pH gradient is a hallmark of cancer metabolism, manifested by extracellular acidosis and intracellular alkalization. While consequences of extracellular acidosis are known, the roles of intracellular alkalization are incompletely understood. By reconstructing and integrating enzymatic pH-d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068141/ https://www.ncbi.nlm.nih.gov/pubmed/30065243 http://dx.doi.org/10.1038/s41467-018-05261-x |
_version_ | 1783343215376596992 |
---|---|
author | Persi, Erez Duran-Frigola, Miquel Damaghi, Mehdi Roush, William R. Aloy, Patrick Cleveland, John L. Gillies, Robert J. Ruppin, Eytan |
author_facet | Persi, Erez Duran-Frigola, Miquel Damaghi, Mehdi Roush, William R. Aloy, Patrick Cleveland, John L. Gillies, Robert J. Ruppin, Eytan |
author_sort | Persi, Erez |
collection | PubMed |
description | A reverse pH gradient is a hallmark of cancer metabolism, manifested by extracellular acidosis and intracellular alkalization. While consequences of extracellular acidosis are known, the roles of intracellular alkalization are incompletely understood. By reconstructing and integrating enzymatic pH-dependent activity profiles into cell-specific genome-scale metabolic models, we develop a computational methodology that explores how intracellular pH (pHi) can modulate metabolism. We show that in silico, alkaline pHi maximizes cancer cell proliferation coupled to increased glycolysis and adaptation to hypoxia (i.e., the Warburg effect), whereas acidic pHi disables these adaptations and compromises tumor cell growth. We then systematically identify metabolic targets (GAPDH and GPI) with predicted amplified anti-cancer effects at acidic pHi, forming a novel therapeutic strategy. Experimental testing of this strategy in breast cancer cells reveals that it is particularly effective against aggressive phenotypes. Hence, this study suggests essential roles of pHi in cancer metabolism and provides a conceptual and computational framework for exploring pHi roles in other biomedical domains. |
format | Online Article Text |
id | pubmed-6068141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60681412018-08-02 Systems analysis of intracellular pH vulnerabilities for cancer therapy Persi, Erez Duran-Frigola, Miquel Damaghi, Mehdi Roush, William R. Aloy, Patrick Cleveland, John L. Gillies, Robert J. Ruppin, Eytan Nat Commun Article A reverse pH gradient is a hallmark of cancer metabolism, manifested by extracellular acidosis and intracellular alkalization. While consequences of extracellular acidosis are known, the roles of intracellular alkalization are incompletely understood. By reconstructing and integrating enzymatic pH-dependent activity profiles into cell-specific genome-scale metabolic models, we develop a computational methodology that explores how intracellular pH (pHi) can modulate metabolism. We show that in silico, alkaline pHi maximizes cancer cell proliferation coupled to increased glycolysis and adaptation to hypoxia (i.e., the Warburg effect), whereas acidic pHi disables these adaptations and compromises tumor cell growth. We then systematically identify metabolic targets (GAPDH and GPI) with predicted amplified anti-cancer effects at acidic pHi, forming a novel therapeutic strategy. Experimental testing of this strategy in breast cancer cells reveals that it is particularly effective against aggressive phenotypes. Hence, this study suggests essential roles of pHi in cancer metabolism and provides a conceptual and computational framework for exploring pHi roles in other biomedical domains. Nature Publishing Group UK 2018-07-31 /pmc/articles/PMC6068141/ /pubmed/30065243 http://dx.doi.org/10.1038/s41467-018-05261-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Persi, Erez Duran-Frigola, Miquel Damaghi, Mehdi Roush, William R. Aloy, Patrick Cleveland, John L. Gillies, Robert J. Ruppin, Eytan Systems analysis of intracellular pH vulnerabilities for cancer therapy |
title | Systems analysis of intracellular pH vulnerabilities for cancer therapy |
title_full | Systems analysis of intracellular pH vulnerabilities for cancer therapy |
title_fullStr | Systems analysis of intracellular pH vulnerabilities for cancer therapy |
title_full_unstemmed | Systems analysis of intracellular pH vulnerabilities for cancer therapy |
title_short | Systems analysis of intracellular pH vulnerabilities for cancer therapy |
title_sort | systems analysis of intracellular ph vulnerabilities for cancer therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068141/ https://www.ncbi.nlm.nih.gov/pubmed/30065243 http://dx.doi.org/10.1038/s41467-018-05261-x |
work_keys_str_mv | AT persierez systemsanalysisofintracellularphvulnerabilitiesforcancertherapy AT duranfrigolamiquel systemsanalysisofintracellularphvulnerabilitiesforcancertherapy AT damaghimehdi systemsanalysisofintracellularphvulnerabilitiesforcancertherapy AT roushwilliamr systemsanalysisofintracellularphvulnerabilitiesforcancertherapy AT aloypatrick systemsanalysisofintracellularphvulnerabilitiesforcancertherapy AT clevelandjohnl systemsanalysisofintracellularphvulnerabilitiesforcancertherapy AT gilliesrobertj systemsanalysisofintracellularphvulnerabilitiesforcancertherapy AT ruppineytan systemsanalysisofintracellularphvulnerabilitiesforcancertherapy |